Immunity

Tiens Group Sticks to Development Belief of “Embracing the World and Serving the World”

Saturday, October 16, 2021 - 2:56pm

Tiens Group, which has always been committed to becoming a leader of global comprehensive health industry, held a 26th Anniversary Carnival celebration on October 16, 2021, which once again conveyed Tienss development belief of Embracing the World and Serving the World to global partners and people around the world who are concerned about development of the comprehensive health industry.

Key Points: 
  • Tiens Group, which has always been committed to becoming a leader of global comprehensive health industry, held a 26th Anniversary Carnival celebration on October 16, 2021, which once again conveyed Tienss development belief of Embracing the World and Serving the World to global partners and people around the world who are concerned about development of the comprehensive health industry.
  • View the full release here: https://www.businesswire.com/news/home/20211016005023/en/
    Tiens Group Sticks to Development Belief of Embracing the World and Serving the World (Photo: Business Wire)
    Tiens has built a global network step by step through 26 years of hard work, from single product to diversified product structure, to comprehensive health services, and then to innovative and integrated development of multiple industrial engagers.
  • Mr. Li Jinyuan, Chairman of Tiens, a global enterprise under influence of the global pandemic, was not astonished and got fully prepared for difficulties.
  • Mr. Li Jinyuan, Chairman of Tiens Group, said that Tiens would go further in the development principle of Embracing the World and Serving the World!

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

Friday, October 15, 2021 - 9:30pm

PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell candidates will be presented at ASN Kidney Week 2021. The data will be presented as an oral abstract by Aimee Payne, M.D., Ph.D., Professor of Dermatology at the University of Pennsylvania’s Perelman School of Medicine and co-chair of the Scientific Advisory Board and co-founder at Cabaletta Bio at the American Society of Nephrology (ASN) Kidney Week 2021 being held virtually from November 4-7, 2021.

Key Points: 
  • PLA2R-CAART is one of seven CAAR T programs that have emerged from the Cabaletta Approach to selective B cell Ablation (CABA) platform.
  • The lead preclinical product candidate, MuSK-CAART, is designed as a potential treatment for patients with MuSK-associated myasthenia gravis, with an IND submission planned by the end of 2021.
  • Primary membranous nephropathy (MN) is a B cell-mediated autoimmune disease that affects the kidneys.
  • Approximately 70-80% of the 15,000 primary MN patients in the U.S. have autoantibodies directed to the phospholipase A2 receptor (PLA2R) on kidney podocytes.

ZOA Energy Joins Forces with TikTok Positivity Influencers to Prove What #KindnessCan Do

Friday, October 15, 2021 - 1:06pm

As a brand rooted in positivity and putting energy behind the actions that make the world a better place, ZOA Energy is proud to announce the company's partnership with TikTok positivity-focused influencers, referred to as "inspirators," JT Laybourne and Ed Delmore to showcase that #KindnessCan change the world.

Key Points: 
  • As a brand rooted in positivity and putting energy behind the actions that make the world a better place, ZOA Energy is proud to announce the company's partnership with TikTok positivity-focused influencers, referred to as "inspirators," JT Laybourne and Ed Delmore to showcase that #KindnessCan change the world.
  • It is the belief of ZOA, Laybourne and Delmore that together, we can all contribute to making the world a kinder place.
  • "The energy that ZOA radiates as a brand is noticeable, and we are so honored to partner with the brand to highlight the importance of kindness," said JT Laybourne, ZOA partner and TikTok inspirator.
  • ZOA is the healthy energy drink created and developed by Dwayne Johnson, Dany Garcia, Dave Rienzi and John Shulman to bring more positive energy to everyday life.

Worldwide Plasma Protein Therapeutics Industry to 2027 - Key Drivers, Restraints and Opportunities - ResearchAndMarkets.com

Thursday, October 14, 2021 - 4:45pm

To treat life-threatening, chronic, and genetic diseases, plasma protein therapeutics are used, consisting of biological medicines, either infused or injected.

Key Points: 
  • To treat life-threatening, chronic, and genetic diseases, plasma protein therapeutics are used, consisting of biological medicines, either infused or injected.
  • The key propellant factor for the plasma protein therapeutics market growth is the rising advents of new plasma-derived therapies.
  • As in the plasma protein therapeutics market for application, the applications of the plasma protein therapeutics include Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Others.
  • Quality and advancements in plasma therapeutics have been the favorable drivers of the global plasma protein therapeutics market to enhance patients' quality of life and assure donor safety.

Dr. Thomas Schenk Joins Welvie Management Team as Chief Medical Officer

Thursday, October 14, 2021 - 3:45pm

CHICAGO, Oct. 14, 2021 /PRNewswire-PRWeb/ -- Welvie, a leading health care decision-support company, has brought Thomas Schenk, M.D., on board as chief medical officer.

Key Points: 
  • CHICAGO, Oct. 14, 2021 /PRNewswire-PRWeb/ -- Welvie, a leading health care decision-support company, has brought Thomas Schenk, M.D., on board as chief medical officer.
  • He will focus on bringing a physician's perspective to Welvie's programs, which help consumers work more effectively with their doctors.
  • Dr. Schenk is a leader in the health care industry with a substantial record of controlling health care costs through efficient care delivery, while also improving quality of care.
  • "Throughout my career, I've been passionate about making health care smarter, more efficient and more effective," said Dr. Schenk.

Versatope Expands Scientific Advisory Board with Dr. Drew Weissman and Board of Directors with Dr. James Kuo and Jeremy Gowler

Thursday, October 14, 2021 - 3:18pm

LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.

Key Points: 
  • LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.
  • Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.
  • Versatope is developing first-in-class vaccines and immuno-therapeutics for infectious and chronic diseases by using their proprietary recombinant outer membrane vesicle (rOMV) platform.
  • Dr. Drew Weissman, MD, PhD,is the Roberts Family Professor of Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania.

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

Thursday, October 14, 2021 - 1:30pm

AUSTIN, Texas and MENLO PARK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Augmenta Bioworks, a biotechnology company leveraging immune profiling technologies to enable breakthroughs in medicine, today announced the publication of a research paper highlighting positive preclinical study results of AUG-3387, a monoclonal antibody (mAb) therapy being developed in collaboration between the two companies for the treatment of SARS-CoV-2 infection. The findings have been published online through the bioRxiv preprint server, under the title “AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo.”

Key Points: 
  • Delivery of the dry powder formulation of AUG-3387 to infected hamsters resulted in a dose-dependent reduction of viral load when administration of the mAb was initiated 24 hours after infection with SARS-CoV-2.
  • This study also represents the first report of successful reduction of viral load using inhaled delivery of a dry powder monoclonal antibody therapeutic for COVID-19 disease.
  • In addition to the in vivo efficacy, AUG-3387 also showed binding activity against the Alpha, Beta, Delta, Gamma, Kappa, Lambda and Mu variants of SARS-CoV-2.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

Renesas Introduces 5V RS-485/422 Transceiver Family With Industry’s Highest EFT Immunity

Thursday, October 14, 2021 - 1:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211014005216/en/
    Renesas' New 5V RS-485/422 Transceivers Deliver the Industry's Highest EFT Immunity (Graphic: Business Wire)
    The new devices build on Renesas current ISL315x 5V RS-485 transceiver family with additional immunity for EFT.
  • In addition to the industrys highest EFT immunity, the RAA78815x family delivers exceptional differential output voltages, featuring 3.1V into the RS-485-required 54 load.
  • Featuring superior EFT immunity, output drive, and supply current levels, the RAA78815x family builds on 50 years experience in RS-485/422 transceiver design to deliver robust solutions for industrial and factory automation.
  • Renesas offers more than 250 Winning Combinations that work together seamlessly for a wide range of applications and end products.

The History of Vaccine Mandates in the US Military, States, and Public Schools Dates Back Over 200 Years, per the A-Mark Foundation

Thursday, October 14, 2021 - 1:55pm

There is also coverage of opposition to vaccine mandates throughout history, and an informative chart showing the vaccine requirements and exemptions for K-12 public schools in all 50 states.

Key Points: 
  • There is also coverage of opposition to vaccine mandates throughout history, and an informative chart showing the vaccine requirements and exemptions for K-12 public schools in all 50 states.
  • We also found that all 50 states currently require vaccinations for viruses such as polio, measles, and rubella for students in K-12 public schools."
  • While all 50 states have had mandated vaccine requirements since 1980 or earlier, there are some exemptions allowed.
  • "We hope that our report will add to available information on vaccine mandates, which should allow people to make more informed decisions about this contentious issue."

Hyris Brings to Market Worldwide a New Test That Can Quickly Detect the Body's T-Cell Immune Response to SARS-CoV-2, Thanks to a Partnership With Singapore's Duke-NUS Medical

Thursday, October 14, 2021 - 12:50pm

The proprietary genetic testing Hyris SystemTM has been successfully used to detect the presence of the Coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and the infection COVID-19 into individuals (SARS-CoV-2 Human test).

Key Points: 
  • The proprietary genetic testing Hyris SystemTM has been successfully used to detect the presence of the Coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and the infection COVID-19 into individuals (SARS-CoV-2 Human test).
  • "Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19."
  • The T-cell clinical test kit was developed through an exclusive licensing agreement between Hyris and Duke-NUS Medical School.
  • Such a test is a prime example of how scientific innovation is key to the fight against the SARS-CoV-2 virus.